{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T10:34:47Z","timestamp":1772447687717,"version":"3.50.1"},"reference-count":33,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T00:00:00Z","timestamp":1668729600000},"content-version":"vor","delay-in-days":1448,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["amjtransplant.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Transplantation"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1111\/ajt.14897","type":"journal-article","created":{"date-parts":[[2018,5,3]],"date-time":"2018-05-03T03:55:35Z","timestamp":1525319735000},"page":"2965-2976","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Five-year outcomes in kidney transplant patients randomized to everolimus with cyclosporine withdrawal or low-exposure cyclosporine versus standard therapy"],"prefix":"10.1016","volume":"18","author":[{"given":"Claudia","family":"Sommerer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Duerr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver","family":"Witzke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Lehner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"Arns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Volker","family":"Kliem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Ackermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Guba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes","family":"Jacobi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingeborg A.","family":"Hauser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rolf","family":"Stahl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petra","family":"Reinke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Rath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justyna","family":"Veit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arianeb","family":"Mehrabi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Porstner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klemens","family":"Budde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1111\/ajt.14897_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1399-0012.2007.00739.x","article-title":"Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity","volume":"22","author":"Flechner","year":"2008","journal-title":"Clin Transplant."},{"key":"10.1111\/ajt.14897_bib2","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1097\/01.TP.0000062837.99400.60","article-title":"Steinberg S; Prograf Study Group. Randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 6 months","volume":"75","author":"Gonwa","year":"2003","journal-title":"Transplantation."},{"key":"10.1111\/ajt.14897_bib3","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1111\/j.1600-6143.2005.01063.x","article-title":"RAD B201 Study Group. Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients","volume":"5","author":"V\u00edtko","year":"2005","journal-title":"Am J Transplant."},{"key":"10.1111\/ajt.14897_bib4","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/01.TP.0000164352.65613.24","article-title":"B251 Study Group. Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, phase III study","volume":"80","author":"Lorber","year":"2005","journal-title":"Transplantation."},{"key":"10.1111\/ajt.14897_bib5","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1056\/NEJMoa067411","article-title":"ELITE-Symphony Study. Reduced exposure to calcineurin inhibitors in renal transplantation","volume":"357","author":"Ekberg","year":"2007","journal-title":"N Engl J Med."},{"key":"10.1111\/ajt.14897_bib6","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1111\/j.1600-6143.2010.03129.x","article-title":"Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients","volume":"10","author":"Tedesco Silva","year":"2010","journal-title":"Am J Transplant."},{"key":"10.1111\/ajt.14897_bib7","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/tri.12252","article-title":"SOCRATES Study Group. A randomized, controlled trial of everolimus-based dual immunosuppression versus standard of care in de novo kidney transplant recipients","volume":"27","author":"Chadban","year":"2014","journal-title":"Transpl Int."},{"key":"10.1111\/ajt.14897_bib8","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1097\/TP.0b013e318224c12d","article-title":"Conversion of long-term kidney transplant recipients from calcineurin inhibitor therapy to everolimus: a randomized, multicenter, 24-month study","volume":"92","author":"Holdaas","year":"2011","journal-title":"Transplantation."},{"key":"10.1111\/ajt.14897_bib9","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/TP.0b013e3181af1df6","article-title":"Minimization of maintenance immunosuppression early after renal transplantation: an interim analysis","volume":"88","author":"Bemelman","year":"2009","journal-title":"Transplantation."},{"key":"10.1111\/ajt.14897_bib10","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(10)62318-5","article-title":"ZEUS Study Investigators. Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial","volume":"377","author":"Budde","year":"2011","journal-title":"Lancet."},{"key":"10.1111\/ajt.14897_bib11","doi-asserted-by":"crossref","first-page":"4138","DOI":"10.1016\/j.transproceed.2009.08.065","article-title":"Renal function outcomes in kidney transplant recipients after conversion to everolimus-based immunosuppression regimen with CNI reduction or elimination","volume":"41","author":"Cataneo-D\u00e0vila","year":"2009","journal-title":"Transplant Proc."},{"key":"10.1111\/ajt.14897_bib12","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1111\/j.1600-6143.2012.04162.x","article-title":"Improved renal function after early conversion from a calcineurin inhibitor to everolimus: a randomized trial in kidney transplantation","volume":"12","author":"Mj\u00f6rnstedt","year":"2012","journal-title":"Am J Transplant."},{"key":"10.1111\/ajt.14897_bib13","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/TP.0b013e3181927a41","article-title":"Sirolimus CONVERT Trial Study Group. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial","volume":"87","author":"Schena","year":"2009","journal-title":"Transplantation."},{"key":"10.1111\/ajt.14897_bib14","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1111\/j.1600-6143.2009.02615.x","article-title":"Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: CONCEPT study","volume":"9","author":"Lebranchu","year":"2009","journal-title":"Am J Transplant."},{"key":"10.1111\/ajt.14897_bib15","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/TP.0b013e3181e11798","article-title":"SMART-Study Group. Renal function, efficacy, and safety of sirolimus and mycophenolate mofetil after short-term calcineurin inhibitor-based quadruple therapy in de novo renal transplant patients: one-year analysis of a randomized multicenter trial","volume":"90","author":"Guba","year":"2010","journal-title":"Transplantation."},{"key":"10.1111\/ajt.14897_bib16","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1038\/ki.2010.492","article-title":"Mycophenolate mofetil-based immunosuppression with sirolimus in renal transplantation: a randomized, controlled Spare-the-Nephron trial","volume":"79","author":"Weir","year":"2011","journal-title":"Kidney Int."},{"key":"10.1111\/ajt.14897_bib17","doi-asserted-by":"crossref","first-page":"11","DOI":"10.5414\/CN108444","article-title":"Renal, efficacy and safety outcomes following late conversion of kidney transplant patients from calcineurin inhibitor therapy to everolimus: the randomized APOLLO study","volume":"83","author":"Budde","year":"2015","journal-title":"Clin Nephrol."},{"key":"10.1111\/ajt.14897_bib18","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1093\/ndt\/gfx075","article-title":"Everolimus with cyclosporine withdrawal or low-exposure cyclosporine in kidney transplantation from month 3: a multicenter, randomized trial","volume":"32","author":"Budde","year":"2017","journal-title":"Nephrol Dial Transplant."},{"key":"10.1111\/ajt.14897_bib19","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1097\/00007890-199506270-00007","article-title":"Predicting glomerular filtration rate after kidney transplantation","volume":"59","author":"Nankivell","year":"1995","journal-title":"Transplantation."},{"key":"10.1111\/ajt.14897_bib20","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron."},{"key":"10.1111\/ajt.14897_bib21","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","article-title":"A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group","volume":"130","author":"Levey","year":"1999","journal-title":"Ann Intern Med."},{"key":"10.1111\/ajt.14897_bib22","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1093\/ndt\/gfl134","article-title":"Switching immunosuppression medications after renal transplantation\u2013a common practice","volume":"21","author":"Meier-Kriesche","year":"2006","journal-title":"Nephrol Dial Transplant."},{"key":"10.1111\/ajt.14897_bib23","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1111\/j.1600-6143.2012.03994.x","article-title":"Conversion from cyclosporine to everolimus at 4.5 months posttransplant: 3-year results from the randomized ZEUS study","volume":"12","author":"Budde","year":"2012","journal-title":"Am J Transplant."},{"key":"10.1111\/ajt.14897_bib24","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/ajt.12952","article-title":"Five-year outcomes in kidney transplant patients converted from cyclosporine to everolimus: the randomized ZEUS study","volume":"15","author":"Budde","year":"2012","journal-title":"Am J Transplant."},{"key":"10.1111\/ajt.14897_bib25","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/tri.12437","article-title":"Renal function three years after early conversion from a calcineurin inhibitor to everolimus: results from a randomized trial in kidney transplantation","volume":"28","author":"Mj\u00f6rnstedt","year":"2015","journal-title":"Transplant Int."},{"key":"10.1111\/ajt.14897_bib26","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1111\/j.1432-2277.2012.01432.x","article-title":"Early conversion to a sirolimus-based, calcineurin-inhibitor-free immunosuppression in the SMART trial: observational results at 24 and 36 months after transplantation","volume":"25","author":"Guba","year":"2012","journal-title":"Transplant Int."},{"key":"10.1111\/ajt.14897_bib27","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/TP.0000000000001098","article-title":"Long-term follow-up of kidney transplant recipients in the Spare-the-Nephron trial","volume":"101","author":"Weir","year":"2017","journal-title":"Transplantation."},{"key":"10.1111\/ajt.14897_bib28","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1097\/01.TP.0000141094.34903.54","article-title":"Everolimus (Certican) 12-month safety and efficacy versus mycophenolate mofetil in de novo renal transplant recipients","volume":"78","author":"Vitko","year":"2004","journal-title":"Transplantation."},{"key":"10.1111\/ajt.14897_bib29","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/j.1600-6143.2004.00389.x","article-title":"Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies","volume":"4","author":"Vitko","year":"2004","journal-title":"Am J Transplant."},{"key":"10.1111\/ajt.14897_bib30","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1097\/01.TP.0000140486.97461.49","article-title":"Everolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: a three-year phase II, randomized, multicenter, open-label study","volume":"78","author":"Nashan","year":"2004","journal-title":"Transplantation."},{"key":"10.1111\/ajt.14897_bib31","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1097\/TP.0000000000001415","article-title":"Histological and extended clinical outcomes after ABO-incompatible renal transplantation without splenectomy or rituximab","volume":"101","author":"Chow","year":"2017","journal-title":"Transplantation."},{"key":"10.1111\/ajt.14897_bib32","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1111\/ajt.12852","article-title":"Risk of metabolic complications in kidney transplantation after conversion to mTOR inhibitor: a systematic review and meta-analysis","volume":"14","author":"Murakami","year":"2014","journal-title":"Am J Transplant."},{"key":"10.1111\/ajt.14897_bib33","doi-asserted-by":"crossref","first-page":"e810","DOI":"10.1097\/MJT.0000000000000150","article-title":"Tacrolimus versus cyclosporine as primary immunosuppressant after renal transplantation: a meta-analysis and economics evaluation","volume":"23","author":"Liu","year":"2016","journal-title":"Am J Ther."}],"container-title":["American Journal of Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fajt.14897","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1600613522098082?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1600613522098082?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/ajt.14897\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T05:22:24Z","timestamp":1761628944000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1600613522098082"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":33,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["S1600613522098082"],"URL":"https:\/\/doi.org\/10.1111\/ajt.14897","relation":{},"ISSN":["1600-6135"],"issn-type":[{"value":"1600-6135","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Five-year outcomes in kidney transplant patients randomized to everolimus with cyclosporine withdrawal or low-exposure cyclosporine versus standard therapy","name":"articletitle","label":"Article Title"},{"value":"American Journal of Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/ajt.14897","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2018 American Society of Transplantation & American Society of Transplant Surgeons. Published by Elsevier Inc. All rights reserved. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}